PRIA Logo™
119-hr-1117119th CongressWALLET

Responsibility in Drug Advertising Act of 2025

Sponsored By: Representative DeLauro, Rosa L. [D-CT-3]

Introduced

Summary

Limits direct-to-consumer advertising of newly approved prescription drugs. This bill would add section 506M to the Federal Food, Drug, and Cosmetic Act to restrict advertising of drugs approved under section 505(c) during their early post-approval period. It phases in a ban for the first three years after approval, allows a narrow third-year waiver if the sponsor shows an affirmative public health value, and lets the Secretary later prohibit advertising if post-approval evidence shows significant adverse health effects.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

Three-year pause on new drug ads

This bill would stop direct-to-consumer ads, including on social media, for three years after FDA approval of many new prescription drugs. It would apply only to drugs approved on or after the date one year before enactment. In the third year, a drug maker could request a waiver. Ads could run if the Secretary finds they have clear public health value. After three years, the Secretary could still prohibit ads if new safety data show significant harms. The Secretary would update advertising rules within one year of enactment and would keep all other ad control powers under current law.

Sponsors & CoSponsors

Sponsor

DeLauro, Rosa L. [D-CT-3]

CT • D

Cosponsors

There are no cosponsors for this bill.

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation